会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Carboxamide compounds and their use as calpain inhibitors IV
    • 羧甲酰胺化合物及其作为钙蛋白酶抑制剂的用途
    • US08598211B2
    • 2013-12-03
    • US12972679
    • 2010-12-20
    • Andreas KlingKatja JantosHelmut MackAchim MöllerWilfried HornbergerGisela BackfischYanbin LaoMarjoleen Nijsen
    • Andreas KlingKatja JantosHelmut MackAchim MöllerWilfried HornbergerGisela BackfischYanbin LaoMarjoleen Nijsen
    • A61K31/4439C07D401/04
    • C07D401/04C07D401/14C07D413/14
    • The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C3-C4-alkyl, C1-C4-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, C3-C6-heterocycloalkyl-C1-C2-alkyl, phenyl-C1-C3-alkyl, pyridin-2-yl-C1-C3-alkyl or 1,3-benzoxazol-2-yl-methyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.
    • 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式I的化合物,其中R 1,R 2,R 3,R 4,R 5,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物及其药学上合适的盐。 在这些化合物中,优选其中R 1为任选取代的苯基-C 1 -C 2 - 烷基或杂芳基-C 1 -C 2烷基,R 2为任选取代的芳基,杂芳基,芳基-C 1 -C 6 - 烷基,芳基-C 2 -C 6 - 烯基 或杂芳基-C 1 -C 4 - 烷基,R 3是C 3 -C 4 - 烷基,C 1 -C 4 - 卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 2烷基,C 3 -C 6 - 杂环烷基-C 1 -C 2 - 烷基,苯基-C 1 -C 3 - 烷基,吡啶-2-基-C 1 -C 3 - 烷基或1,3-苯并恶唑-2-基 - 甲基,R 4和R 5彼此独立地是卤素 ,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。
    • 8. 发明授权
    • Substituted amides, their production and their use
    • 取代酰胺,其生产和使用
    • US06448254B1
    • 2002-09-10
    • US09647677
    • 2000-10-03
    • Wilfried LubischAchim MöllerHans-Jörg TreiberMonika Knopp
    • Wilfried LubischAchim MöllerHans-Jörg TreiberMonika Knopp
    • C07C31121
    • C07D213/56C07C311/21C07D215/36C07D239/70C07D239/96
    • Amides of the general formula I and their tautomeric and isomeric forms, possible enantiomeric and diastereomeric forms, as well as possible physiologically tolerable salts, in which the variables have the following meanings: R1 [sic] can be C1-C6-alkyl, phenyl, naphthyl, quinolyl, pyridyl, pyrimidyl, pyridazyl, quinazolyl and quinoxalyl, where the rings can additionally be substituted by up to 2 radicals R4 [sic], and R2 [sic] is —(CH2)m—R8 [sic], where R8 [sic] can be phenyl, cyclohexyl- or indolyl and m=1 to 6, and X is a bond, —CH2—, —CH2CH2—, —CH═CH—, —C≡C—, —CONH—, —SO2NH— [sic], and and [sic] R1—X [sic] together are also  and R3 [sic] is hydrogen and CO—NR6R7 [sic], R4 [sic] is hydrogen, C1-C4-alkyl [sic], which is branched and unbranched, and —O—C1-C4-alkyl [sic]; R5 [sic] is hydrogen, C1-C4-alkyl [sic], which is branched or unbranched, and —O—C1-C4-alkyl [sic]; R6 [sic] is hydrogen, C1-C6-alkyl, which is branched and unbranched, and R7 [sic] is hydrogen, C1-C6-alkyl, which is branched or unbranched, and n is is [sic] a number 0, 1 or 2.
    • 通式I的酰胺及其互变异构体和异构体形式,可能的对映异构体和非对映体形式,以及可能的生理上可耐受的盐,其中变量具有以下含义:R 1 [C 1-6]可以是C 1 -C 6 - 烷基,苯基,萘基 ,喹啉基,吡啶基,嘧啶基,哒嗪基,喹唑啉基和喹喔啉基,其中环可以另外被至多2个基团R 4 [sic]取代,并且R 2是 - (CH 2)m -R 8 [sic],其中R 8 [ ]可以是苯基,环己基或吲哚基并且m = 1至6,X是键,-CH 2 - , - CH 2 CH 2 - , - CH = CH - , - C≡C - , - CONH - , - SO 2 NH- ],并且R 1-X [sic]一起也是且R 3 [sic]是氢且CO-NR 6 R 7 [sic],R 4 [sic]是氢,C 1 -C 4 - 烷基[ 非支链和-O-C 1 -C 4 - 烷基[sic]; R 5 [sic]是氢,C 1 -C 4 - 烷基[sic],其是支链或非支链的,和-O-C 1 -C 4 - 烷基[ R 6是氢,C 1 -C 6 - 烷基,其是支链和非支链的,并且R 7 [sic]是氢,C 1 -C 6 - 烷基,其是支链或 不分支,而且是数字0,1或2。
    • 10. 发明申请
    • CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS IV
    • 羧酰胺化合物及其作为抑制剂的用途IV
    • US20110152325A1
    • 2011-06-23
    • US12972679
    • 2010-12-20
    • Andreas KlingKatja JantosHelmut MackAchim MöllerWilfried HornbergerGisela BackfischYanbin LaoMarjoleen Nijsen
    • Andreas KlingKatja JantosHelmut MackAchim MöllerWilfried HornbergerGisela BackfischYanbin LaoMarjoleen Nijsen
    • A61K31/4439C07D401/04A61P25/28A61P25/00A61P25/08A61P25/04A61P13/12A61P35/00A61P31/18A61P37/02A61P33/06
    • C07D401/04C07D401/14C07D413/14
    • The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted aryl, hetaryl, aryl-C1-C6-alkyl, aryl-C2-C6-alkenyl or hetaryl-C1-C4-alkyl, R3 is C3-C4-alkyl, C1-C4-haloalkyl, C2-C4-alkenyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C2-alkyl, C3-C6-heterocycloalkyl-C1-C2-alkyl, phenyl-C1-C3-alkyl, pyridin-2-yl-C1-C3-alkyl or 1,3-benzoxazol-2-yl-methyl, R4 and R5 independently of one another are halogen, CF3, CHF2, CH2F, C1-C2-alkyl or C1-C2-alkoxy, and m and n independently of one another are 0 or 1.
    • 本发明涉及新的羧酰胺化合物及其用于制备药物的用途。 羧酰胺化合物是钙蛋白酶(钙依赖性半胱氨酸蛋白酶)的抑制剂。 因此,本发明还涉及这些羧酰胺化合物用于治疗与升高的钙蛋白酶活性相关的病症的用途。 羧酰胺化合物是通式I的化合物,其中R 1,R 2,R 3,R 4,R 5,m和n具有权利要求书和描述中所述的含义,其互变异构体,其水合物及其药学上合适的盐。 在这些化合物中,优选其中R 1为任选取代的苯基-C 1 -C 2 - 烷基或杂芳基-C 1 -C 2烷基,R 2为任选取代的芳基,杂芳基,芳基-C 1 -C 6 - 烷基,芳基-C 2 -C 6 - 烯基 或杂芳基-C 1 -C 4 - 烷基,R 3是C 3 -C 4 - 烷基,C 1 -C 4 - 卤代烷基,C 2 -C 4 - 烯基,C 3 -C 6 - 环烷基,C 3 -C 6 - 环烷基-C 1 -C 2烷基,C 3 -C 6 - 杂环烷基-C 1 -C 2 - 烷基,苯基-C 1 -C 3 - 烷基,吡啶-2-基-C 1 -C 3 - 烷基或1,3-苯并恶唑-2-基 - 甲基,R 4和R 5彼此独立地是卤素 ,CF 3,CHF 2,CH 2 F,C 1 -C 2 - 烷基或C 1 -C 2 - 烷氧基,m和n彼此独立地为0或1。